Quantcast

Latest Graft-versus-host disease Stories

2011-10-31 22:47:51

Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD. "Tregs play a dominant role in transplantation tolerance," said Claudio Anasetti, M.D., corresponding...

2011-08-17 08:52:00

NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical research center, announced that its portfolio company Enlivex Therapeutics (92% owned by Hadasit Bio) has completed the recruitment of three out of four groups in its Phase I / II clinical trial using its treatment for the reduction of graft versus...

2011-08-12 06:00:00

PRINCETON, N.J., Aug. 12, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2011. Soligenix's revenues for the second quarter of 2011 were approximately $406,000 as compared to $445,000 for the second quarter of 2010. The slight decrease in revenues was primarily a result of completion in April 2011 of the initial year of its FDA Orphan Products grant for...

2011-08-09 07:18:37

(Ivanhoe Newswire) -- New research finds that growing blood stem cells in the laboratory for about a week may help to overcome one of the most difficult roadblocks to successful transplantation, immune rejection. The study may lead to more promising therapeutic strategies for transplanting blood stem cells. Hematopoietic stem cells (HSCs) are cells that can give rise to all of the different types of blood cells. Transplantation of HSCs has been used to treat leukemia, lymphoma, and other...

2011-08-04 14:05:43

New research finds that growing blood stem cells in the laboratory for about a week may help to overcome one of the most difficult roadblocks to successful transplantation, immune rejection. The study, published by Cell Press in the August issue of the journal Cell Stem Cell, may lead to more promising therapeutic strategies for transplanting blood stem cells. Hematopoietic stem cells (HSCs) are cells that can give rise to all of the different types of blood cells. Transplantation of HSCs has...

2011-07-28 07:47:00

PRINCETON, N.J., July 28, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) for the development and commercialization of orBec® (oral beclomethasone dipropionate or Oral BDP) into the European territory. As part of the amended agreement, Sigma-Tau has made a $5 million...

2011-07-14 15:41:56

St. Jude Children's Research Hospital investigators reported markedly improved survival of pediatric patients transplanted for high-risk leukemia regardless of donor; cite treatment advances and better donor selection Bone marrow transplant survival more than doubled in recent years for young, high-risk leukemia patients treated at St. Jude Children's Research Hospital, with patients who lacked genetically matched donors recording the most significant gains. The results are believed to be the...

2011-07-07 19:00:43

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy. The finding means that nearly all patients in need of a transplant can find donors, according to Johns...

2011-07-07 05:45:00

MELBOURNE, Australia, July 7, 2011 /PRNewswire/ -- Key points: Mesoblast's first Phase 3 trial submission cleared by United States Food and Drug Administration (FDA) Rapid clearance (within 30 days) further validation of Mesoblast's clinical, regulatory, and manufacturing capabilities Mesoblast's proprietary adult stem cells expand hematopoietic precursor cells in umbilical cord blood 40-fold, enabling rapid bone marrow reconstitution with lowered risk of life-threatening Graft Versus...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related